Page header

Position of the Transparency Council – Revestive (teduglutide)

At its meeting on 23 December 2024, the Transparency Council adopted position No. 157/2024 on the appropriateness of issuing approvals for reimbursement of the drug Revestive (teduglutide) for the indication: short bowel syndrome

 

Publication of the position >>